Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...

The odds of major perioperative bleeding were increased 18.1-fold for patients who underwent emergent hepatic surgery, 10.9-fold for emergent splenic surgery, and 9.6-fold for emergent pancreatic ...

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with incident bipolar disorder (BD), accordi ...

Pain intensity linked to increased likelihood of using cigarettes, e-cigarettes, cannabis, lower likelihood of alcohol use ...

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...

Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the ...

Burnout in US oncologists has increased over the past 10 years, according to results of 2 surveys. 1 Researchers compared results of a 2023 survey of 328 oncologists to results of a 2013 survey of ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...